Alkem Labs receives ₹32.5 Cr balance consideration for trade generics business transfer

Alkem Laboratories Limited has announced the receipt of the balance sale consideration of ₹32.5 crore for the transfer of its trade generics business. This payment was made by Alkem Wellness Limited, ...

Alkem Laboratories Limited has announced the receipt of the balance sale consideration of ₹32.5 crore for the transfer of its trade generics business. This payment was made by Alkem Wellness Limited, a wholly-owned subsidiary, on December 30, 2025. This brings the total aggregate sale consideration to ₹532.5 crore, as per the terms of the Business Transfer Agreement dated September 26, 2025. The transfer of the trade generics business to Alkem Wellness was effected on a slump sale basis, effective from October 1, 2025. This update follows previous intimations to the stock exchanges on December 10, 2024, and September 26, 2025, regarding this business transfer.

Limitations of AI summaries

AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.

Platforms like Prysm provide stock-level and portfolio-level analysis.

Why is Alkem Laboratories Limited in the news today?

Alkem Laboratories Limited (ALKEM) is in the news due to the completion of the sale and receipt of the balance consideration signifies a positive step in the company's restructuring efforts and financial closure of the transaction.

RestructuringOther Corporate ActionsOther Company Updates
Alkem Laboratories LimitedALKEMhttps://prysm.fi/v2/analyze/ALKEM

AI-Powered Summary

Market Context

Top Queries

More News

Explore Prysm Tools

Related Stories

Alkem Labs receives ₹32.5 Cr balance consideration for trade generics business transfer

December 30, 2025, 11:41 AM

AI Sentiment Analysis

Top Queries to Ask About Alkem Laboratories Limited

More Details on This News

Alkem Laboratories Limited has announced the receipt of the balance sale consideration of ₹32.5 crore for the transfer of its trade generics business. This payment was made by Alkem Wellness Limited, a wholly-owned subsidiary, on December 30, 2025.

This brings the total aggregate sale consideration to ₹532.5 crore, as per the terms of the Business Transfer Agreement dated September 26, 2025. The transfer of the trade generics business to Alkem Wellness was effected on a slump sale basis, effective from October 1, 2025.

This update follows previous intimations to the stock exchanges on December 10, 2024, and September 26, 2025, regarding this business transfer.

See What Deep Dive Gives You — in Seconds

“what happens when you click Deep Dive “

Instant AI Summary - “Get clean, noise-free earnings breakdowns.”

PDF Insights - “Download detailed, AI-generated reports.”

Metrics Explained -“Key ratios & trends explained in simple language.”

Want to know if this news pushes your stock up or down?

Just tap

deep dive

More News on Alkem Laboratories Limited

Discover more trending news on Prysm

View All